Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate.

The 2nd Oligonucleotides CMC & Analytical Development Summit returns this August to Boston. 70+ industry leaders will unite at this unique forum dedicated to CMC and Analytical Experts.

Across 3 days, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind.

Built with experts from AstraZeneca, Alexion Pharmaceuticals, Biogen , revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit.

• Explore analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance
• Overcome the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development
• Get interactive in roundtable discussions, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape
• Facilitate cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications
• Turbocharge novel and complex oligonucleotide development in an in-depth workshop outlining CMC, Analytical Characterization and Impurity Control of conjugates

Download your Full Event Guide Here for more details on what you can expect at the 2nd Oligonucleotides CMC & Analytical Development Summit. Including the expert speaker faculty, a full in-depth agenda and the incredible networking and collaboration opportunities on offer this year.